公开(公告)号：US20090181887A1

公开(公告)日：2009-07-16

申请号：US12066178

申请日：2006-09-06

申请人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

发明人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

IPC分类号： A61K38/22 ,  A61P25/00 ,  G01N33/566

CPC分类号： A61K38/26 ,  G01N2333/605 ,  G01N2500/02 ,  G01N2800/08 ,  Y02A50/49

摘要： The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.

摘要翻译： 本发明涉及适用于治疗或预防来自胆道树的胆汁运动障碍和/或疼痛和/或不适的分子，组合物和方法。 肽激素胰高血糖素样肽-1（GLP-1）在胃肠道中具有抗分泌作用和平滑肌松弛性质。 GLP-1以几种形式存在，其中天然存在的GLP-1分子是GLP-1（1-37），GLP-1（7-37）和酰胺化型GLP-1（1-36）酰胺，GLP -1（7-36）酰胺。 在GLP-1分子中包括能够结合并激活GLP-1受体的其它分子。 GLP-1分子可以是具有一个或多个氨基酸取代或修饰的GLP-1的天然存在或同源物。 GLP-1分子用于制造用于治疗或预防胆汁运动障碍和/或来自胆道树的疼痛和/或不适的药物。

公开(公告)号：US20080171700A1

公开(公告)日：2008-07-17

申请号：US11578135

申请日：2005-04-07

申请人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

发明人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

IPC分类号： A61K38/25 ,  A61P5/00 ,  A61P3/00 ,  A61P3/04

CPC分类号： A61K38/25

摘要： The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency. Furthermore, the present invention relates to the use of a secretagogue, such as a ghrelin-like compound, for the production of a medicament for preventing weight increase in an individual either: a) being converted from a hyperthyroidic state to euthyroid state, or b) in remission from being converted from a hyperthyroidic state to euthyroid state.

摘要翻译： 本发明涉及生长激素（GH）促分泌素如生长素释放肽样化合物在个体中用于预防或治疗生长素释放肽缺乏症和/或与之相关的不良症状的药物的用途 有获得由医疗和/或病理状况引起的部分或完全的生长素释放肽缺乏的风险。 本发明还涉及促分泌素化合物在制备用于预防或治疗以下中的一种或多种的药物中的用途：脂肪量的损失，瘦体重的减少，体重减轻，恶病质，食欲不振，免疫功能障碍 ，营养不良，睡眠模式紊乱，困倦，减少肠道吸收和/或肠道运动问题，或者有遭受生长素释放肽缺乏症的个体。 此外，本发明涉及促分泌素如生长素释放肽样化合物在制备用于预防个体体重增加的药物中的用途：a）从甲状腺功能亢进状态转变为甲状腺功能状态，或b ）缓解从甲状腺功能亢进状态转变为甲状腺功能状态。